PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy |
| November 25, 2019 | November 2019 Bond Updates |
|
SOUTH PLAINFIELD, N.J., Nov. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the United States Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for risdiplam (RG7916) for the treatment of spinal muscular... |
| View more at: https://prnmedia.prnewswire.com:443/news-releases/ptc-therapeutics-announces-fda-grants-priority-review-to-risdiplam-for-the-treatment-of-spinal-muscular-atrophy-300964301.html |
| Related News |
|